Shield Diagnostics To Launch Seven More Products

14 July 1996

- Shield Diagnostics, a producer of diagnostic kits for heart disease and syphilis, has announced fiscal 1995 pretax profits of L276,100 ($428,921) on a turnover of L5.8 million ($9.01 million), up 22%. Gross margins declined 5% from 48% due to the price increase of its syphilis products. The company invested L639,500 ($993,463) in R&D, a 43% rise on the previous year. As a result it is to launch seven additional products this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight